Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Common Equity (2018 - 2025)

Dna X's Common Equity history spans 8 years, with the latest figure at -$8.0 million for Q4 2025.

  • Quarterly results put Common Equity at -$8.0 million for Q4 2025, down 39.56% from a year ago — trailing twelve months through Dec 2025 was -$8.0 million (down 39.56% YoY), and the annual figure for FY2025 was -$8.0 million, down 39.56%.
  • Common Equity for Q4 2025 was -$8.0 million at Dna X, down from -$701000.0 in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $23.1 million in Q3 2023 to a low of -$8.0 million in Q4 2025.
  • The 5-year median for Common Equity is $16.4 million (2024), against an average of $12.3 million.
  • The sharpest move saw Common Equity surged 208.74% in 2023, then crashed 125.48% in 2024.
  • Year by year, Common Equity stood at $18.6 million in 2021, then rose by 7.6% to $20.0 million in 2022, then rose by 11.59% to $22.4 million in 2023, then crashed by 125.48% to -$5.7 million in 2024, then tumbled by 39.56% to -$8.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$8.0 million, -$701000.0, and -$1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.